Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

Is there a role for post-operative chemoradiation therapy in fully resected, margin-negative T3N1 NSCLC?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Yale School of Medicine

I assume you're talking about T3 for chest wall invasion, and I think the answer is probably no routine role for RT for this individual risk factor. If you look at surgical series, invasion of the chest wall IS a risk factor for both positive surgical margins, and local recurrence. But if you limit ...

For breast cancer patients requiring staging, should one order a CT C/A/P & bone scan or PET scan?

2
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

For locally advanced disease (T4 or N2), I would favor PET/CT because of the higher yield for identifying metastatic disease. It is also important for the radiation oncologist because of the higher likelihood of identifying of involved IM nodes and level 3a and supraclavicular nodes which can change...

When would you use concurrent cetuximab with radiation for a patient with H&N cancer who is not a good candidate for concurrent chemotherapy?

7
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Michigan

Additional data has been added since I have addressed this question in 2015: the role of concurrent cet-RT in HNC patients who cannot receive chemotherapy. The large majority of these patients are elderly with heavy smoking/drinking history, and typically have non-HPV related Sqcca associated with p...

Should the incorporation of thoracic RT be standard in patients with extensive stage small cell lung cancer?

7
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Pennsylvania Health System

The jury is really still out on the issue of whether or not to add thoracic radiation therapy to prophylactic cranial irradiation (PCI) in patients with extensive-stage small cell lung cancer. The published data cited above, Slotman et al. in Lancet last Fall 2014, indicate that there may be an over...

Would you treat a patient with small cell lung cancer (limited to lung and mediastinum) but also with a malignant pleural effusion with upfront definitive thoracic chemoradiation?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Quillen VA Medical Center

I would treat such a case as EXTENSIVE DISEASE. That means chemotherapy with 4 cycles of Plat/Etop, and restage with PET. If the pleural disease has gone by imaging or/and pleural tap, I would add thoracic radiotherapy 30 gy/10 fractions and PCI 2.5 gy X ten. If the pleural space remains positive, I...

Can chemotherapy be used instead of radiation therapy in a patient with extensive stage small cell lung cancer who presents with epidural spinal cord compression?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Johns Hopkins University/Sidney Kimmel Cancer Center

I think it would have to be done on a case-by-case basis, and the answer is likely "Not a good idea." Chemo can make SCLC shrink a lot, but you'd really have to monitor day by day with CAT scans. And it unlikely to take the pressure off the spinal cord arteries within hours to days, as is needed. Th...

Should immunotherapy be standard of care for metastatic MSI-high colorectal cancer?

2
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Duke University School of Medicine

It should be a treatment option but not yet in the first line. My first option for MSI-H patients is to enroll in an immunotherapy trial. If not available, I'll usually reserve single-agent PD-1 inhibitors until after second line therapy. Recent data suggests that the Ipilimumab-nivolumab combo migh...

Do you omit anthracyclines in perioperative chemotherapy for gastric cancer?

2 Answers

Mednet Member
Mednet Member
Medical Oncology · Memorial Sloan Kettering Cancer Center

The available data would suggest a very small benefit, if at all, for anthracyclines in the locally advanced setting.Although the MAGIC study established ECF as a standard-of-care, a contemporaneous French FFCD study revealed nearly identical outcomes with 5-FU/cisplatin alone.More recently, the res...

Which embolization approach is preferred for liver metastases from well differentiated neuroendocrine tumors?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · UH Seidman Cancer Center, Case Western Reserve University

Treatment options for metastatic GEP-NETs have evolved in recent years including PRRT which definitely affects our decisions for when and who will be eligible for liver-directed therapies (LDTs). In general, LDTs are appropriate for patients with G1/2 well diff. diffuse, unresectable liver metastas...

When do you give treatment breaks for patients with NSCLC undergoing chemoradiation with serious toxicity?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Cleveland Clinic

I agree with @Dr. First Last's approach. I am very aggressive in not introducing treatment breaks during radiotherapy. One approach that I occasionally use to "make up" for dose issues when a break is inevitable is to accelerate at the end of treatment to make up for the break rather than to specifi...